Renvistobart

DB19065InvestigationalProtein Based Therapies

Renvistobart is under investigation in clinical trial NCT02913313 (A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors).

Mechanism: Pharmacologically active on T-cell immunoreceptor with Ig and ITIM domains
Curator reviewed
Also known as: Anti-TIGIT Monoclonal Antibody BMS-986207
Code names: BMS-986207

Resolves to

Compound

UNII81J55YFQ16CAS2725062-35-9

Targets

Q495A1TIGIT

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Renvistobart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account